Cargando…

Changes of Pulmonary Pathology and Gene Expressions After Simvastatin Treatment in the Monocrotaline-Induced Pulmonary Hypertension Rat Model

BACKGROUND AND OBJECTIVES: Simvastatin's properties are suggestive of a potential pathophysiologic role in pulmonary hypertension. The objectives of this study were to investigate changes of pulmonary pathology and gene expressions, including endothelin (ET)-1, endothelin receptor A (ERA), indu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yun Hee, Kim, Kwan Chang, Cho, Min-Sun, Hong, Young Mi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Cardiology 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193043/
https://www.ncbi.nlm.nih.gov/pubmed/22022327
http://dx.doi.org/10.4070/kcj.2011.41.9.518
_version_ 1782213830780125184
author Lee, Yun Hee
Kim, Kwan Chang
Cho, Min-Sun
Hong, Young Mi
author_facet Lee, Yun Hee
Kim, Kwan Chang
Cho, Min-Sun
Hong, Young Mi
author_sort Lee, Yun Hee
collection PubMed
description BACKGROUND AND OBJECTIVES: Simvastatin's properties are suggestive of a potential pathophysiologic role in pulmonary hypertension. The objectives of this study were to investigate changes of pulmonary pathology and gene expressions, including endothelin (ET)-1, endothelin receptor A (ERA), inducible nitric oxide synthase (NOS2), endothelial nitric oxide synthase (NOS3), matrix metalloproteinase (MMP) 2, tissue inhibitor of matrix metalloproteinases (TIMP) and caspase 3, and to evaluate the effect of simvastatin on monocrotaline (M)-induced pulmonary hypertension. MATERIALS AND METHODS: Six week old male Sprague-Dawley rats were treated, as follows: control group, subcutaneous (sc) injection of saline; M group, sc injection of M (60 mg/kg); and simvastatin group, sc injection of M (60 mg/kg) plus 10 mg/kg/day simvastatin orally. RESULTS: On day 28, right ventricular hypertrophy (RVH) significantly decreased in the simvastatin group compared to the M group. Similarly, right ventricular pressure significantly decreased in the simvastatin group on day 28. From day 7, the ratio of medial thickening of the pulmonary artery was significantly increased in the M group, but there was no significant change in the simvastatin group. The number of muscular pulmonary arterioles was significantly reduced in the simvastatin group. On day 5, gene expressions of ET-1, ERA, NOS2, NOS3, MMP and TIMP significantly decreased in the simvastatin group. CONCLUSION: Administration of simvastatin exerted weak inhibitory effects on RVH and on the number of muscular pulmonary arterioles, during the development of M-induced pulmonary hypertension in rats. Simvastatin decreased gene expressions on day 5.
format Online
Article
Text
id pubmed-3193043
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher The Korean Society of Cardiology
record_format MEDLINE/PubMed
spelling pubmed-31930432011-10-21 Changes of Pulmonary Pathology and Gene Expressions After Simvastatin Treatment in the Monocrotaline-Induced Pulmonary Hypertension Rat Model Lee, Yun Hee Kim, Kwan Chang Cho, Min-Sun Hong, Young Mi Korean Circ J Original Article BACKGROUND AND OBJECTIVES: Simvastatin's properties are suggestive of a potential pathophysiologic role in pulmonary hypertension. The objectives of this study were to investigate changes of pulmonary pathology and gene expressions, including endothelin (ET)-1, endothelin receptor A (ERA), inducible nitric oxide synthase (NOS2), endothelial nitric oxide synthase (NOS3), matrix metalloproteinase (MMP) 2, tissue inhibitor of matrix metalloproteinases (TIMP) and caspase 3, and to evaluate the effect of simvastatin on monocrotaline (M)-induced pulmonary hypertension. MATERIALS AND METHODS: Six week old male Sprague-Dawley rats were treated, as follows: control group, subcutaneous (sc) injection of saline; M group, sc injection of M (60 mg/kg); and simvastatin group, sc injection of M (60 mg/kg) plus 10 mg/kg/day simvastatin orally. RESULTS: On day 28, right ventricular hypertrophy (RVH) significantly decreased in the simvastatin group compared to the M group. Similarly, right ventricular pressure significantly decreased in the simvastatin group on day 28. From day 7, the ratio of medial thickening of the pulmonary artery was significantly increased in the M group, but there was no significant change in the simvastatin group. The number of muscular pulmonary arterioles was significantly reduced in the simvastatin group. On day 5, gene expressions of ET-1, ERA, NOS2, NOS3, MMP and TIMP significantly decreased in the simvastatin group. CONCLUSION: Administration of simvastatin exerted weak inhibitory effects on RVH and on the number of muscular pulmonary arterioles, during the development of M-induced pulmonary hypertension in rats. Simvastatin decreased gene expressions on day 5. The Korean Society of Cardiology 2011-09 2011-09-29 /pmc/articles/PMC3193043/ /pubmed/22022327 http://dx.doi.org/10.4070/kcj.2011.41.9.518 Text en Copyright © 2011 The Korean Society of Cardiology http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, Yun Hee
Kim, Kwan Chang
Cho, Min-Sun
Hong, Young Mi
Changes of Pulmonary Pathology and Gene Expressions After Simvastatin Treatment in the Monocrotaline-Induced Pulmonary Hypertension Rat Model
title Changes of Pulmonary Pathology and Gene Expressions After Simvastatin Treatment in the Monocrotaline-Induced Pulmonary Hypertension Rat Model
title_full Changes of Pulmonary Pathology and Gene Expressions After Simvastatin Treatment in the Monocrotaline-Induced Pulmonary Hypertension Rat Model
title_fullStr Changes of Pulmonary Pathology and Gene Expressions After Simvastatin Treatment in the Monocrotaline-Induced Pulmonary Hypertension Rat Model
title_full_unstemmed Changes of Pulmonary Pathology and Gene Expressions After Simvastatin Treatment in the Monocrotaline-Induced Pulmonary Hypertension Rat Model
title_short Changes of Pulmonary Pathology and Gene Expressions After Simvastatin Treatment in the Monocrotaline-Induced Pulmonary Hypertension Rat Model
title_sort changes of pulmonary pathology and gene expressions after simvastatin treatment in the monocrotaline-induced pulmonary hypertension rat model
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193043/
https://www.ncbi.nlm.nih.gov/pubmed/22022327
http://dx.doi.org/10.4070/kcj.2011.41.9.518
work_keys_str_mv AT leeyunhee changesofpulmonarypathologyandgeneexpressionsaftersimvastatintreatmentinthemonocrotalineinducedpulmonaryhypertensionratmodel
AT kimkwanchang changesofpulmonarypathologyandgeneexpressionsaftersimvastatintreatmentinthemonocrotalineinducedpulmonaryhypertensionratmodel
AT chominsun changesofpulmonarypathologyandgeneexpressionsaftersimvastatintreatmentinthemonocrotalineinducedpulmonaryhypertensionratmodel
AT hongyoungmi changesofpulmonarypathologyandgeneexpressionsaftersimvastatintreatmentinthemonocrotalineinducedpulmonaryhypertensionratmodel